Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease. It also engages in developing KB105, which is in preclinical studies to treat Lamellar Ichthyosis, which is an autosomal recessive disorder. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is based in Pittsburgh, Pennsylvania.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone412-586-5830
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees37
Next Earnings Date5/6/2019 (Estimated)
OptionableNot Optionable
Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions
What is Krystal Biotech's stock symbol?
Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."
How were Krystal Biotech's earnings last quarter?
Krystal Biotech Inc (NASDAQ:KRYS) posted its quarterly earnings data on Monday, November, 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.26). View Krystal Biotech's Earnings History.
When is Krystal Biotech's next earnings date?
What price target have analysts set for KRYS?
6 equities research analysts have issued 1 year price targets for Krystal Biotech's stock. Their predictions range from $32.00 to $57.50. On average, they expect Krystal Biotech's share price to reach $40.3750 in the next year. This suggests a possible upside of 61.4% from the stock's current price. View Analyst Price Targets for Krystal Biotech.
What is the consensus analysts' recommendation for Krystal Biotech?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Krystal Biotech.
What are Wall Street analysts saying about Krystal Biotech stock?
Here are some recent quotes from research analysts about Krystal Biotech stock:
- 1. According to Zacks Investment Research, "Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. " (3/22/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $32 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our model currently received the majority of valuation contribution from KB103 for the treatment of DEB patients, with modest contribution from KB105 for ARCI." (1/15/2019)
- 3. Cantor Fitzgerald analysts commented, "We rate Krystal Biotech Overweight. Krystal focuses on developing and delivering gene therapy products for dermatological diseases. Its lead programs KB103 is in Phase 1/2 development for the treatment of dystrophic epidermolysis bullosa. Valuation Summary The probability adjusted, fully-taxed (21%) NPV (15% discount rate) of potential cash flows through 2032 is $355 million, or ~$24 per share. Including a technology value of $50 million (~$3/share) and our estimate of 2019 YE cash of $88 million (~$6/share), we arrive at our valuation of $493 million or $34/share." (12/19/2018)
Has Krystal Biotech been receiving favorable news coverage?
News coverage about KRYS stock has been trending somewhat positive this week, InfoTrie reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Krystal Biotech earned a media sentiment score of 0.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the near future.
Who are some of Krystal Biotech's key competitors?
Some companies that are related to Krystal Biotech include Rubius Therapeutics (RUBY), Momenta Pharmaceuticals (MNTA), Alector (ALEC), Editas Medicine (EDIT), Iovance Biotherapeutics (IOVA), Fate Therapeutics (FATE), Coherus Biosciences (CHRS), Sangamo Therapeutics (SGMO), Autolus Therapeutics (AUTL), Vericel (VCEL), BioCryst Pharmaceuticals (BCRX), NanoString Technologies (NSTG), Cellectis (CLLS), Nightstar Therapeutics (NITE) and BAVARIAN NORDIC/S (BVNRY).
What other stocks do shareholders of Krystal Biotech own?
Who are Krystal Biotech's key executives?
Krystal Biotech's management team includes the folowing people:
- Mr. Krish S. Krishnan, Pres, CEO & Chairman (Age 54)
- Ms. Suma M. Krishnan, Founder, COO & Director (Age 54)
- Ms. Pooja Agarwal, VP of Product Devel. (Age 40)
- Mr. Antony A. Riley, Chief Financial Officer (Age 52)
- Ms. Gloria Lin, Accounting Mang.
When did Krystal Biotech IPO?
(KRYS) raised $30 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO.
Who are Krystal Biotech's major shareholders?
Krystal Biotech's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (8.56%), Frazier Management LLC (6.06%), Great Point Partners LLC (3.41%), Artal Group S.A. (1.91%), Sphera Funds Management LTD. (1.21%) and Geode Capital Management LLC (0.42%). Company insiders that own Krystal Biotech stock include Antony A Riley, Daniel Janney, Krish S Krishnan, R Douglas Norby and Suma Krishnan. View Institutional Ownership Trends for Krystal Biotech.
Which major investors are buying Krystal Biotech stock?
KRYS stock was bought by a variety of institutional investors in the last quarter, including Great Point Partners LLC, FMR LLC, Frazier Management LLC, Sphera Funds Management LTD., Artal Group S.A., Barclays PLC, Alps Advisors Inc. and Bank of New York Mellon Corp. Company insiders that have bought Krystal Biotech stock in the last two years include Antony A Riley, Daniel Janney, Krish S Krishnan, R Douglas Norby and Suma Krishnan. View Insider Buying and Selling for Krystal Biotech.
How do I buy shares of Krystal Biotech?
Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Krystal Biotech's stock price today?
One share of KRYS stock can currently be purchased for approximately $25.02.
How big of a company is Krystal Biotech?
Krystal Biotech has a market capitalization of $361.04 million. The company earns $-10,890,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. Krystal Biotech employs 37 workers across the globe.
What is Krystal Biotech's official website?
How can I contact Krystal Biotech?
Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at 412-586-5830.
MarketBeat Community Rating for Krystal Biotech (NASDAQ KRYS)
MarketBeat's community ratings are surveys of what our community members think about Krystal Biotech and other stocks. Vote "Outperform" if you believe KRYS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KRYS will underperform the S&P 500 over the long term. You may vote once every thirty days.
